Eclipsys Corporation (NASDAQ:ECLP), The Outcomes Company®, today announced its response to the Center for Medicare and Medicaid Services’(CMS) final rule on ‘meaningful use’ of an electronic health records (EHR). Countering opinions describing any criteria to include Computerized Provider Order Entry (CPOE) in 2011 as “too ambitious,” Eclipsys applauds CMS for coming forward to add electronic medication order entry as a requirement for achieving “meaningful use.” According to the final rule regulation, at least 30 percent of patients with a medication order must have that order entered through a CPOE solution. Moreover, in Stage 2 of ‘meaningful use,’ scheduled for 2013, the CPOE medication order requirement doubles to 60 percent. A sole focus on CPOE related to patient medication is a significant change from the interim final rule CPOE requirement of 10 percent of orders, regardless of order type. “The addition of medication order entry as a requirement will directly support patient safety, clinical decision support and decrease the risk of medication errors that daily impacts the lives and well-being of patients and their families,” said Phil Pead, president and chief executive officer. “What’s important to note is that the landmark Institute of Medicine report, ‘To Err is Human,’ was published 11 years ago, calling for expanded use of CPOE to reduce avoidable medical errors and deaths. The passage of the CMS’ Electronic Health Record Incentive Program is an unprecedented opportunity to move forward the quality and safety of care for all of us. As a leading provider of health care technology, we know meaningful CPOE adoption is achievable and we strongly support this effort to expedite implementing a technology that prevents human errors and has been proven to reduce costs, injuries and deaths.” In additional response to the ‘meaningful use’ final rule, Eclipsys also supports:
A Client Base Ranked No. 1 in Meeting Composite CMS Quality Measures; Dominates Magnet HospitalsIn addition to CPOE adoption, the Eclipsys client base outperforms industry peers on multiple fronts. Eclipsys’ clinical information system clients dominate the field of Magnet Recognition Program® hospitals. Magnet status provides consumers with a benchmark to measure the quality of care they can expect to receive. Eclipsys clients represent 45 percent of all organizations receiving Magnet status. The company’s clients also represent more than 80 percent of the organizations listed as “America’s Best Hospitals,” according to the U.S. News & World Report’s 2009 ranking. Further, Eclipsys clients account for eight of the top 10 U.S. health systems and 27 of the top 51 health systems based on their clinical performance across the entire system according to the June 2010 Thomson Reuters study. Client Webinar Scheduled Eclipsys will host an educational client webinar on Friday, July 16, at 11 a.m. Eastern Time, entitled “Final Ruling on Meaningful Use of EHR and its Impact on You.” The webinar will focus on final ruling updates and how clients can leverage Sunrise Enterprise™ 5.5 to help their organization achieve meaningful use. Eclipsys clients can register at https://swrt.worktankseattle.com/webcast/5089/preview.aspx About the Final Rule On July 13, 2010, CMS issued the much–anticipated final rule on ‘Meaningful Use. The information technology regulations establish the requirements that eligible professionals and hospitals must adhere to in order to fully meet requirements for financial incentives authorized under the HITECH ACT of the American Recovery & Reinvestment Act (ARRA) of 2009. The final rule was accompanied by one on certification and standards from the Office of the National Coordinator for Healthcare IT. The final federal register version of the regulation will be issued on July 28, 2010. For more information, see http://www.cms.gov/EHRIncentivePrograms/ The CMS EHR Incentive Program Final rule can be found at: http://www.ofr.gov/OFRUpload/OFRData/2010-17207_PI.pdf The ONC Standards, Implementation Specifications and Certification Criteria Final Rule can be found at: http://www.ofr.gov/OFRUpload/OFRData/2010-17210_PI.pdf About Eclipsys Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email email@example.com. Statements in this news release concerning the implementation of and features and benefits provided by Eclipsys software, ARRA qualification, receipt of stimulus funds, and evidence-based content and services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and client-specific configuration of Eclipsys software can be complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. ARRA qualification requires compliance with standards that are still evolving, and satisfaction of those standards may be delayed. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys, The Outcomes Company, and Sunrise Enterprise are either registered trademarks or trademarks of Eclipsys Corporation (or its subsidiaries) in the United States and certain other countries. Other product and company names in this news release are or may be trademarks of their respective companies.